正文参考文献

[1] Abat C, Huart M, Garcia V et al. Enterococcus faecalis urinary-tract infections: Do they have a zoonotic origin? The Journal of infection 2016; 73: 305-13.

[2] Guiton S, Hannan J, Ford B et al. Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infect Immun 2013, 81(1): 329-39.

[3] Zhang S, Ren L, Li Y et al. Bacteriology and drug susceptibility analysis of pus from patients with severe intra-abdominal infection induced by abdomin ADDIN EN.CITE  ADDIN EN.CITE.DATA [1]al trauma. Experimental and therapeutic medicine 2014; 7: 1427-31.

[4] DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41: 327-33.

[5] Caballero-Granado FJ, Becerril B, Cuberos L et al. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2001; 32: 587-94.

[6] Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012; 3: 421-33.

[7] Nishiyama M, Iguchi A, Suzuki Y. Identification of Enterococcus faecium and Enterococcus faecalis as vanC-type Vancomycin-Resistant Enterococci (VRE) from sewage and river water in the provincial city of Miyazaki, Japan. Journal of environmental science and health Part A, Toxic/hazardous substances & environmental engineering 2015; 50: 16-25.

[8] Yamanaka H, Takagi T, Ohsawa M et al. Identification and characterization of vancomycin-resistant Enterococcus species frequently isolated from laboratory mice. Experimental animals 2014; 63: 297-304.

[9] Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2011; 15: e732-9.

[10] Falagas ME, Vouloumanou EK, Samonis G et al. Fosfomycin. Clinical microbiology reviews 2016; 29: 321-47

[11] Grayson ML, Macesic N, Trevillyan J et al. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2015; 61: 1141-3.

[12] Oliva A, Furustrand Tafin U, Maiolo EM et al. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrobial agents and chemotherapy 2014; 58: 1284-93.

[13] Tang HJ, Chen CC, Zhang CC et al. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagnostic microbiology and infectious disease 2013; 77: 254-7.

[14] “Performance Standards for Antimicrobial Susceptibility Testing: 26th Informational Supplement M100-S26,” CLSI, 2016.

[15] Maasjost J, Muhldorfer K, Cortez de Jackel S et al. Antimicrobial Susceptibility Patterns of Enterococcus faecalis and Enterococcus faecium Isolated from Poultry Flocks in Germany. Avian diseases 2015; 59: 143-8.

[16] Medell M, Hart M, Batista ML. In vitro antimicrobial susceptibility in Enterococcus faecalis and Enterococcus faecium isolated from hospitalized patients. Biomedica: revista del Instituto Nacional de Salud 2014; 34 Suppl 1: 50-7.

[17] 杨青, 俞云松, 林洁. “2005—2014 年 CHINET 肠球菌属细菌耐药性监测” 中国感染与化疗杂志, 2016; 16(2), 146-152.

[18] Chen C, Xu X, Qu T et al. Prevalence of the fosfomycin-resistance determinant, fosB3, in Enterococcus faecium clinical isolates from China. Journal of medical microbiology 2014; 63: 1484-9.

[19] Malik RK, Montecalvo MA, Reale MR et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. The Pediatric infectious disease journal 1999; 18: 352-6.

[20] Kiss B, Schondorf D, Studer UE et al. Stricture of the afferent isoperistaltic tubular segment: a late and rare cause of bilateral dilation of the upper urinary tract after ileal bladder substitution. Urology 2013; 82: 466-70.

[21] 傅祝英杰, 吴湜, 郭燕. “金黄色葡萄球菌临床分离株磷霉素耐药性及fos耐药基因的检测”中国感染与化疗杂志, 15(03), pp209-213.

[22] 张劲丰, 吴英, 杨祚升. “emeA基因的存在及表达与肠球菌属耐药的相关性研究”中华医院感染学杂志, 22(01), pp1-3.

[23] Xu X, Chen C, Lin D et al. The fosfomycin resistance gene fosB3 is located on a transferable, extrachromosomal circular intermediate in clinical Enterococcus faecium isolates. PloS one 2013;

[24] Rigsby RE, Fillgrove KL, Beihoffer LA et al. Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily. Methods in enzymology 2005; 401: 367-79.

[25] Lee SY, Park YJ, Yu JK et al. Prevalence of acquired fosfomycin resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in   Korea and IS26-composite transposon surrounding fosA3. The Journal of antimicrobial chemotherapy 2012; 67: 2843-7.

[26] Jiang Y, Shen P, Wei Z et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. International journal of antimicrobial agents 2015; 45: 66-70.

[27] Villa L, Guerra B, Schmoger S et al. IncA/C Plasmid Carrying bla_(NDM-1), bla_(CMY-16), and fosA3 in a Salmonella enterica Serovar Corvallis Strain Isolated from a Migratory Wild Bird in Germany. Antimicrobial agents and chemotherapy 2015; 59: 6597-600.

[28] Cao M, Bernat BA, Wang Z et al. FosB, a cysteine-dependent fosfomycin resistance protein under the control of sigma(W), an extracytoplasmic-function sigma factor in Bacillus subtilis. Journal of bacteriology 2001; 183: 2380-3.

[29] Thompson MK, Keithly ME, Goodman MC et al. Structure and function of the genomically encoded fosfomycin resistance enzyme, FosB, from Staphylococcus aureus. Biochemistry 2014; 53: 755-65.

[30] Qu TT, Shi KR, Ji JS et al. Fosfomycin resistance among vancomycin-resistant enterococci owing to transfer of a plasmid harbouring the fosB gene. International journal of antimicrobial agents 2014; 43: 361-5.

[31] Sun L, Zhang P, Qu T et al. Identification of Novel Conjugative Plasmids with Multiple Copies of fosB that Confer High-Level Fosfomycin Resistance to Vancomycin-Resistant Enterococci. Frontiers in microbiology 2017; 8: 1541.

[32] Christie-Oleza JA, Nogales B, Lalucat J et al. TnpR encoded by an ISPpu12 isoform regulates transposition of two different ISL3-like insertion sequences in Pseudomonas stutzeri after conjugative interaction. Journal of bacteriology 2010; 192: 1423-32.

[33] Kallastu A, Horak R, Kivisaar M. Identification and characterization of IS1411, a new insertion sequence which causes transcriptional activation of the phenol degradation genes in Pseudomonas putida. Journal of bacteriology 1998; 180: 5306-12.

[34] Yap KP, Ho WS, Gan HM et al. Global MLST of Salmonella Typhi Revisited in Post-genomic Era: Genetic Conservation, Population Structure, and Comparative Genomics of Rare Sequence Types. Frontiers in microbiology 2016; 7: 270.

[35] Pericas JM, Cervera C, del Rio A et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2014; 20: O1075-83.

[36] Miro JM, Cervera C, Garcia-de-la-Maria C et al. Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity. Scandinavian journal of infectious diseases 2008; 40: 968-72.

[37] Hopefl AW. Overview of synergy with reference to double beta-lactam combinations. DICP: the annals of pharmacotherapy 1991; 25: 972-7. 

综述参考文献

[1] Gilmore MS, Clewell DB, Ike Y et al. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection 2014.

[2] Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? The Lancet Infectious diseases 2001; 1: 314-25.

[3] Hayakawa K, Martin ET, Gudur UM et al. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. Antimicrobial agents and chemotherapy 2014; 58: 3968-75.

[4] Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012; 3: 421-33.

[5] Falagas ME, Vouloumanou EK, Samonis G et al. Fosfomycin. Clinical microbiology reviews 2016; 29: 321-47

[6] Raz R. Fosfomycin: an old--new antibiotic. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2012; 18: 4-7.

[7] Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. The Lancet Infectious diseases 2010; 10: 43-50.

[8] Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969; 166: 122-3.

[9] Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46: 1069-77.

[10] Skarzynski T, Mistry A, Wonacott A et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 1996; 4: 1465-74.

[11] Borisova M, Gisin J, Mayer C. Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. Microb Drug Resist 2014; 20: 231-7.

[12] Xu L, Wu D, Liu L et al. Characterization of mycobacterial UDP-N-acetylglucosamine enolpyruvyle transferase (MurA). Research in microbiology 2014; 165: 91-101.

[13] Docobo-Perez F, Drusano GL, Johnson A et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrobial agents and chemotherapy 2015; 59: 5602-10

[14] Docobo-Perez F, Drusano GL, Johnson A et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrobial agents and chemotherapy 2015; 59: 5602-10.

[15] Carlone NA, Borsotto M, Cuffini AM et al. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents. European urology 1987; 13 Suppl 1: 86-91.

[16] Yokota S, Okabayashi T, Yoto Y et al. Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor. FEMS microbiology letters 2010; 310: 84-90.

[17] Guggenbichler JP, Bonatti H, Rottensteiner F. [Resistance of staphylococci to intracellular killing by macrophages--a new pathophysiologic concept of acute hematogenous osteomyelitis in childhood and its therapeutic consequences]. Padiatrie und Padologie 1989; 24: 21-32.

[18] Trautmann M, Meincke C, Vogt K et al. Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics. Infection 1992; 20: 350-4.

[19] Valour F, Trouillet-Assant S, Riffard N et al. Antimicrobial activity against intraosteoblastic Staphylococcus aureus. Antimicrobial agents and chemotherapy 2015; 59: 2029-36.

[20] Okada N, Nishio M, Danbara H. Intracellular activity of fosfomycin against two distinct enteropathogenic bacteria, Salmonella enterica and Listeria monocytogenes, alive inside host cells. Chemotherapy 2003; 49: 49-55.

[21]Kihlstrom E, Andaker L. Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae. The Journal of antimicrobial chemotherapy 1985; 15: 723-8.

[22] Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2014; 34: 845-57.

[23] Perdigao-Neto LV, Oliveira MS, Rizek CF et al. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrobial agents and chemotherapy 2014; 58: 1763-7.

[24] Kaase M, Szabados F, Anders A et al. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. Journal of clinical microbiology 2014; 52: 1893-7.

[25] Lu CL, Liu CY, Huang YT et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrobial agents and chemotherapy 2011; 55: 4295-301.

[26] Pogue JM, Marchaim D, Abreu-Lanfranco O et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. The Journal of antibiotics 2013; 66: 625-7.

[27] Pogue JM, Marchaim D, Abreu-Lanfranco O et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. The Journal of antibiotics 2013; 66: 625-7.

[28] Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. European urology 2008; 54: 1164-75.

[29] Cho YH, Jung SI, Chung HS et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. International urology and nephrology 2015; 47: 1059-66.

[30] Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990; 18 Suppl 2: S65-9.

[31] Roussos N, Karageorgopoulos DE, Samonis G et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International journal of antimicrobial agents 2009; 34: 506-15.

[32] Docobo-Perez F, Drusano GL, Johnson A et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrobial agents and chemotherapy 2015; 59: 5602-10.

[33] Frossard M, Joukhadar C, Erovic BM et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrobial agents and chemotherapy 2000; 44: 2728-32.

[34] Sauermann R, Schwameis R, Fille M et al. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. The Journal of antimicrobial chemotherapy 2009; 64: 821-3.

[35] Segre G, Bianchi E, Cataldi A et al. Pharmacokinetic profile of fosfomycin trometamol (Monuril). European urology 1987; 13 Suppl 1: 56-63.

[36] Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.

[37] Sanchez Navarro MD, Sayalero Marinero ML, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections. The Journal of antimicrobial chemotherapy 2002; 50: 67-72.

[38] Thomas K, Weinbren MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. The Journal of antimicrobial chemotherapy 2006; 57: 367-8.

[39] Parker S, Lipman J, Koulenti D et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International journal of antimicrobial agents 2013; 42: 289-93.

[40] Hara T, Araake M, Watabe H. [Antibacterial activities of fosfomycin against several fresh clinical isolates--comparison of the test methods for antibacterial activity]. The Japanese journal of antibiotics 2002; 55: 844-54.

[41] Frossard M, Joukhadar C, Erovic BM et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrobial agents and chemotherapy 2000; 44: 2728-32.

[42] Matzi V, Lindenmann J, Porubsky C et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. The Journal of antimicrobial chemotherapy 2010; 65: 995-8.

[43] Borsa F, Leroy A, Fillastre JP et al. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrobial agents and chemotherapy 1988; 32: 938-41.

[44] Inouye S, Niizato T, Takeda U et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. Journal of pharmacobio-dynamics 1982; 5: 659-69.

[45] Yoshiyama Y, Yazaki T, Wong PC et al. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2001; 7: 243-6.

[46] Keating GM. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013; 73: 1951-66.

[47] Keating GM. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013; 73: 1951-66.

[48] Fernandes Mda S, Fujimoto G, de Souza LP et al. Dissemination of Enterococcus faecalis and Enterococcus faecium in a ricotta processing plant and evaluation of pathogenic and antibiotic resistance profiles. Journal of food science 2015; 80: M765-75.

[49] Murray BE. The life and times of the Enterococcus. Clinical microbiology reviews 1990; 3: 46-65.

[50] Yuen GJ, Ausubel FM. Enterococcus infection biology: lessons from invertebrate host models. J Microbiol 2014; 52: 200-10.

[51] Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infection control and hospital epidemiology 2008; 29: 996-1011.

[52] Rice LB, Lakticova V, Helfand MS et al. In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci. The Journal of infectious diseases 2004; 190: 2162-6.

[53] Abamecha A, Wondafrash B, Abdissa A. Antimicrobial resistance profile of Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma, Ethiopia. BMC research notes 2015; 8: 213.

[54] Sidhu JP, Skelly E, Hodgers L et al. Prevalence of enterococcus species and their virulence genes in fresh water prior to and after storm events. Environmental science & technology 2014; 48: 2979-88.

[55] Soheili S, Ghafourian S, Sekawi Z et al. Wide distribution of virulence genes among Enterococcus faecium and Enterococcus faecalis clinical isolates. TheScientificWorldJournal 2014; 2014: 623174.

[56] Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? The Journal of antimicrobial chemotherapy 2013; 68: 731-42.

[57] Nishiyama M, Iguchi A, Suzuki Y. Identification of Enterococcus faecium and Enterococcus faecalis as vanC-type Vancomycin-Resistant Enterococci (VRE) from sewage and river water in the provincial city of Miyazaki, Japan. Journal of environmental science and health Part A, Toxic/hazardous substances & environmental engineering 2015; 50: 16-25.

[58] Szakacs TA, Kalan L, McConnell MJ et al. Outbreak of vancomycin-susceptible Enterococcus faecium containing the wild-type vanA gene. Journal of clinical microbiology 2014; 52: 1682-6.

[59] DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41: 327-33.

[60] Caballero S, Carter R, Ke X et al. Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae. PLoS pathogens 2015; 11: e1005132.

[61] Cattoir V, Giard JC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert review of anti-infective therapy 2014; 12: 239-48.

[62] Merlo TP, Dabul AN, Camargo IL. Different VanA Elements in E. faecalis and in E. faecium Suggest at Least Two Origins of Tn1546 Among VRE in a Brazilian Hospital. Microb Drug Resist 2015; 21: 320-8.

[63] Cremniter J, Mainardi JL, Josseaume N et al. Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium. The Journal of biological chemistry 2006; 281: 32254-62.

[64] Bae MH, Kim J, Sung H et al. Evaluation of iNtRON VRE vanA/vanB real-time PCR for follow-up surveillance of VRE-infected or colonized patients. Diagnostic microbiology and infectious disease 2013; 77: 292-5.

[65] Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagnostic microbiology and infectious disease 2007; 57: 459-65.

[66] Jung E, Byun S, Lee H et al. Vancomycin-resistant Enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization. American journal of infection control 2014; 42: 1062-6.

[67] Marshall SH, Donskey CJ, Hutton-Thomas R et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrobial agents and chemotherapy 2002; 46: 3334-6.

[68] Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. American journal of infection control 2007; 35: 521-6.

[69] Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). International journal of antimicrobial agents 2009; 34: 121-30.

[70] Berenger R, Bourdon N, Auzou M et al. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Medecine et maladies infectieuses 2011; 41: 405-9.

[71] Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). J Chemother 2011; 23: 200-6.

[72] de Cueto M, Hernandez JR, Lopez-Cerero L et al. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae]. Enfermedades infecciosas y microbiologia clinica 2006; 24: 613-6.

[73] Gobernado M. [Fosfomycin]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2003; 16: 15-40.

[74] Khan IU, Mirza IA, Ikram A et al. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2014; 24: 914-7.

[75] Stock I. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria]. Medizinische Monatsschrift fur Pharmazeuten 2015; 38: 4-11.

[76] Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. The Journal of antimicrobial chemotherapy 1999; 43: 211-7.

[77] Perri MB, Hershberger E, Ionescu M et al. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagnostic microbiology and infectious disease 2002; 42: 269-71.

[78] Superti S, Dias CA, d'Azevedo PA. In vitro fosfomycin activity in vancomycin-resistant Enterococcus faecalis. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2009; 13: 123-4.

[79] Brodrick HJ, Raven KE, Harrison EM et al. Whole-genome sequencing reveals transmission of vancomycin-resistant Enterococcus faecium in a healthcare network. Genome medicine 2016; 8: 4.

[80] Descourouez JL, Jorgenson MR, Wergin JE et al. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrobial agents and chemotherapy 2013; 57: 1518-20.

[81] Pogue JM, Marchaim D, Abreu-Lanfranco O et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. The Journal of antibiotics 2013; 66: 625-7.

[82] Oliva A, Furustrand Tafin U, Maiolo EM et al. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrobial agents and chemotherapy 2014; 58: 1284-93.

[83] Etienne J, Gerbaud G, Courvalin P et al. Plasmid-mediated resistance to fosfomycin in Staphylococcus epidermidis. FEMS microbiology letters 1989; 52: 133-7.

[84] Liao RZ, Thiel W. Determinants of regioselectivity and chemoselectivity in fosfomycin resistance protein FosA from QM/MM calculations. The journal of physical chemistry B 2013; 117: 1326-36.

[85] Vialou V, Thibault M, Kaska S et al. Differential induction of FosB isoforms throughout the brain by fluoxetine and chronic stress. Neuropharmacology 2015; 99: 28-37.

[86] Garcia P, Arca P, Evaristo Suarez J. Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrobial agents and chemotherapy 1995; 39: 1569-73.

[87] Fillgrove KL, Pakhomova S, Schaab MR et al. Structure and mechanism of the genomically encoded fosfomycin resistance protein, FosX, from Listeria monocytogenes. Biochemistry 2007; 46: 8110-20.

[88] Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2011; 15: e732-9.

[89] Jiang Y, Shen P, We